Pharmacokinetic study of Benralizumab in Healthy Chinese Subjects

Study identifier:D3250C00034

ClinicalTrials.gov identifier:NCT03928262

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1, Randomized, Single-blind Study to Assess the Safety, Tolerability, and Pharmacokinetics of Benralizumab Administered as Single Subcutaneous Dose in Healthy Chinese Subjects

Medical condition

Healthy subjects

Phase

Phase 1

Healthy volunteers

Yes

Study drug

-

Sex

All

Actual Enrollment

36

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 02 Apr 2019
Primary Completion Date: 12 Aug 2019
Study Completion Date: 12 Aug 2019

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2020 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria